Echo Report Summary - Mrs. Kadeeja, 48F, 16-Sep-2022

Patient Details

• Age/Sex: 48 years, Female
• Date: 16 September 2022

Measurements at a Glance

Doppler Findings - Explained

Key Findings Explained

1. Regional Wall Motion Abnormality (RWMA)

• Basal and Mid Inferior wall: Thinned and scarred - This is the hallmark of a prior myocardial infarction (old MI) in the territory of the Right Coronary Artery (RCA). Thinning and scarring (fibrosis) of the inferior wall indicate that infarcted myocardium was replaced by scar tissue - this is an old, healed MI.
• Mid Infero-lateral wall: Hypokinetic - This region is moving less than normal. This adjacent area may represent ischemic but not yet infarcted tissue, or a border zone of an old MI extending into the left circumflex (LCx) territory.

2. Mild LV Systolic Dysfunction (EF 48%)

3. LV Diastolic Dysfunction

4. Mild Mitral Regurgitation (MR)

5. Valves

• Aortic valve: Thickened with trivial AR - mild age-related calcific changes, not hemodynamically significant at this stage.
• Tricuspid: Trivial TR - clinically insignificant.
• Pulmonary valve: Normal

6. Great Vessels and Pericardium - All Normal

Clinical Summary

Mrs. Kadeeja had a prior inferior wall myocardial infarction (old RCA territory MI). The basal and mid inferior walls are thinned and scarred (non-viable tissue from old infarct). Adjacent infero-lateral wall is hypokinetic (ischemic or border zone). The result is mildly reduced systolic function (EF 48%) and Grade 1 diastolic dysfunction. There is secondary (functional) mild mitral regurgitation due to papillary muscle involvement from the inferior MI. No pulmonary hypertension. Chambers are not significantly enlarged. No pericardial effusion.

What This Means Going Forward

• This patient likely needs coronary angiography (or already had one) to assess the extent of coronary artery disease.
• Management typically includes: ACE inhibitor/ARB, beta-blocker, statin, aspirin (the standard post-MI regimen).
• The EF of 48% should be monitored - if it drops below 40%, guidelines recommend consideration of ICD (implantable defibrillator) for sudden death prevention.
• The mild MR should be followed with repeat echo; it often stays stable if the underlying ischemia is treated.
• Since this is labeled "an old echo report," a repeat current echo would be valuable to see if the EF has improved, worsened, or stayed the same over the years since 2022.

Today's Echo (01-Jul-2026) vs Old Echo (16-Sep-2022) - Mrs. Kadeeja K, 51F

Side-by-Side Comparison

What Has Changed and Why - Key Analysis

1. Mitral Regurgitation: Mild → SEVERE (Most Important Change)

2. EF Drop: 48% → 43%

3. Diastolic Pattern Shift: Grade 1 → Apparent "Normalization" (E>A, E:A = 1.375)

4. New: Mild Pulmonary Artery Hypertension

5. New Finding: IAS Thinned and Aneurysmal

• Paradoxical embolism (if a patent foramen ovale is also present)
• Stroke/TIA (especially important if there is atrial fibrillation risk) This likely developed or became more apparent due to the increased left atrial pressure from the severe MR pushing against the septum.

6. Extended Infero-lateral Wall Scarring

The Critical Paradox: Asymptomatic Despite Severe MR

• The LV is dilating (50 → 54 mm)
• EF is declining (48 → 43%)
• LA is enlarging (32 → 39 mm)
• Mild PAH has appeared

Key distinction: For primary MR (degenerative), early intervention in asymptomatic patients with EF <60% or LV dilation is clearly indicated. For secondary MR (her case - ischemic), the valve is not the primary disease - the myocardium is. Fixing the valve alone does not fix the underlying ischemic cardiomyopathy, and the benefit of surgery for secondary MR is less well-established. - Washington Manual, Secondary MR section; Fuster & Hurst's The Heart 15e

What Needs to Happen Now

1. Optimize GDMT immediately if not already maximized:
   • ACE inhibitor or ARB (reduces LV remodeling and MR severity by reducing afterload)
   • Beta-blocker (reduce heart rate, improve LV filling time and remodeling)
   • Mineralocorticoid receptor antagonist (spironolactone/eplerenone for EF <50%)
   • Consider SGLT2 inhibitor (now a Class I recommendation for HFmrEF)
   • Statin + antiplatelets for the ischemic substrate
2. Coronary angiography / assessment for revascularization:
   • The infero-lateral wall has now scarred further. If there is any viable but jeopardized myocardium, revascularization could slow further decline and reduce MR severity.
3. Repeat echo in 3-6 months to track EF trajectory.
4. Assess for ICD indication: If EF drops to ≤35% on optimal medical therapy for ≥3 months, an ICD for sudden cardiac death prevention is a Class I indication.
5. Discuss TEER (MitraClip): If she develops symptoms or her EF continues to fall, she may become a candidate for transcatheter mitral valve repair. The COAPT trial showed benefit of MitraClip in patients with severe secondary MR and HF on GDMT.
6. Stroke risk from IAS aneurysm: Evaluate for coexisting PFO (bubble contrast echo or TEE). Given her age and ischemic history, anticoagulation strategy should be reviewed.

Summary in Plain Language

Mrs. Kadeeja's heart has shown significant deterioration over 4 years. The most important change is that her mitral valve leak has gone from mild to severe, driven by her old inferior heart attack spreading further into the infero-lateral wall. Her heart pump is weaker (EF 48% → 43%), the heart chambers are enlarging, and lung pressures are beginning to rise slightly. Despite having no symptoms right now, the echo data shows the heart is under increasing strain. She needs urgent specialist review to optimize all medications and assess if any intervention is needed, because asymptomatic does not mean safe in this context - silent damage is occurring.

Will Mitral Valve Repair Help Mrs. Kadeeja?

First: What Type of MR Does She Have?

The Core Problem with Repair in Her Case

Repair vs. Replacement in severe ischemic MR: no difference in LV remodeling or survival, but MR recurred in 59% of repaired valves vs. only 4% of replaced valves at 2 years. (PMID: 35366026)

So What Are the Options? A Clear Framework

Option 1: Optimize Medical Therapy (First Priority - She is Asymptomatic)

• ACEi/ARB - reduces MR severity by lowering afterload (vasodilation shrinks the LV, reducing leaflet tethering)
• Beta-blocker - slows remodeling, improves EF
• SGLT2 inhibitor (e.g., empagliflozin/dapagliflozin) - Class I for HFmrEF (EF 43%)
• Mineralocorticoid antagonist (spironolactone)
• Statin + antiplatelet for the ischemic substrate

Option 2: Coronary Revascularization (Important to Assess First)

• Rescue hibernating myocardium
• Improve EF
• Reduce MR severity by restoring papillary muscle blood supply

Option 3: TEER - MitraClip (The Most Relevant Interventional Option for Her)

• No open-heart surgery - avoids the high surgical risk of her dilated, weakened heart
• COAPT trial (the landmark RCT): in patients with severe secondary MR on GDMT who remained symptomatic, MitraClip reduced heart failure hospitalizations by 47% and all-cause mortality by 38% at 2 years vs. GDMT alone
• The COAPT sub-study (PMID: 38795108) showed TEER also improved left atrial function - directly relevant since her LA is already dilating

• Severe secondary MR ✅ (she has this)
• On maximally tolerated GDMT ✅ (she needs to be)
• Symptomatic (NYHA II-IV) ⚠️ - she is currently asymptomatic, so not yet a candidate
• LVEF >20% ✅ (her EF is 43%)
• LVEDD <70mm ✅ (her LVIDd is 54mm)

Option 4: Surgical Mitral Valve Replacement (Not First-Line, But an Option if CABG Needed)

Bottom Line for Her Specific Situation

The key message: Her MR is a symptom of the ventricular disease, not the primary disease. Fixing the valve without addressing the underlying ischemic cardiomyopathy and optimizing medical therapy is unlikely to help, and may expose her to unnecessary surgical risk. The right path is aggressive medical therapy now, monitor closely, and have a low threshold to refer for TEER at the first sign of symptoms.

Non-Medication Care for Mrs. Kadeeja

1. Daily Monitoring at Home

Weight - Most Important Daily Check

• Weigh herself every morning - same time, after emptying bladder, before eating
• Alert rule: if weight increases by more than 1-1.5 kg in a day, or 2 kg in 2-3 days - this signals fluid retention (early heart failure decompensation) and the doctor must be called immediately, even before symptoms appear
• Keep a weight diary or use a simple app

Symptom Awareness - Know the Warning Signs

2. Diet

Salt (Sodium) Restriction - High Priority

• Target <2 grams sodium per day (roughly <5 g table salt)
• Avoid: pickles, pappad, processed foods, packaged snacks, instant noodles, canned items, soy sauce
• No adding extra salt at the table
• Kerala cuisine specifically: reduce use of salted fish (upperi meen), salted buttermilk, and coconut-based preparations with high salt

Fluid Intake

• She is currently compensated, so strict fluid restriction is not yet needed
• However, avoid excessive fluid loading - aim for approximately 1.5-2 litres total fluid per day
• If she ever develops ankle swelling or breathlessness, restrict to 1.5 litres/day and call the doctor

Diet Quality

• Fruits and vegetables daily - potassium-rich foods (banana, coconut water in small amounts, orange) help counter salt retention, but if she is on spironolactone, check potassium levels before increasing these
• Reduce saturated fats (coconut oil in large amounts, red meat, fried food) - she has underlying coronary artery disease
• Mediterranean or DASH diet pattern is ideal - shown to reduce cardiovascular events
• No alcohol - cardiotoxic, worsens cardiomyopathy and MR directly

Weight Management

• Calculate BMI. If overweight, each kg of excess weight adds cardiac workload
• However: avoid extreme calorie restriction - cardiac cachexia (muscle wasting) in heart failure is a bad prognostic sign; she should maintain healthy muscle mass

3. Physical Activity and Cardiac Rehabilitation

What to Do

• Cardiac rehabilitation (supervised exercise program) - Class I recommendation for patients with reduced EF after MI and heart failure
• In the absence of a formal program: 30 minutes of moderate-pace walking, 5 days a week
• Moderate = she can talk comfortably while walking, but not sing
• Build up gradually from 10-15 minutes if deconditioned

What to Avoid

• Heavy weightlifting, isometric straining (straining against resistance)
• Breath-holding during exertion (Valsalva-type activities)
• Competitive sports or sudden bursts of intense exertion

Why It Matters for Her

• Improves EF modestly (can recover 3-5 percentage points)
• Reduces sympathetic overactivation (same mechanism as beta-blockers but additive)
• Lowers cardiac event risk and hospitalizations
• Improves quality of life even before symptoms develop

4. Device Therapy Assessment - Important at Her EF Level

ICD (Implantable Cardioverter Defibrillator)

• Current EF is 43% - just above the threshold
• The Class I indication for ICD is: EF ≤35% + at least 40 days post-MI + NYHA Class II/III + on GDMT - Braunwald's Heart Disease, Device Therapy Guidelines
• She does not yet qualify, but if EF drops to ≤35% on repeat echo (which is a real risk given the downward trajectory), ICD becomes strongly indicated
• ICD prevents sudden cardiac death from ventricular arrhythmias - a major cause of death in ischemic cardiomyopathy

CRT (Cardiac Resynchronization Therapy)

• Only indicated if she has LBBB with QRS ≥150ms on ECG plus EF ≤35%
• Needs an ECG to assess - not determinable from echo alone
• If QRS is broad (dyssynchrony), CRT can improve EF by 5-10% and reduce MR severity

5. Sleep Assessment

Screen for Sleep Apnea

• Sleep apnea (both obstructive and central) is very common in heart failure and independently worsens cardiac outcomes - Braunwald's Heart Disease
• Symptoms: loud snoring, witnessed breathing pauses, waking unrefreshed, daytime sleepiness
• If suspected: refer for sleep study (polysomnography)
• Obstructive sleep apnea: CPAP treatment reduces sympathetic activation, lowers BP, reduces arrhythmia risk
• Central sleep apnea in HFrEF: more complex - ASV (adaptive servo-ventilation) has shown harm in HFrEF and should be avoided

6. Surveillance and Follow-up Schedule

7. Psychological and Social Care

• Anxiety and depression are extremely common in asymptomatic patients with known heart disease - often the knowledge of the diagnosis itself causes distress
• Untreated depression worsens adherence to diet, exercise, and medications - directly worsening cardiac outcomes
• Screen at each visit. Refer for counselling or support group if needed
• Family education - her family (especially those in UAE - note the WhatsApp name "Haleema UAE") should be informed about warning signs and when to seek emergency care
• What to do in an emergency: nearest hospital with a cardiac ICU; she should ideally carry a card summarizing her diagnosis, medications, and the fact she has an EF of 43%

8. Vaccinations - Often Forgotten

• Annual influenza vaccine - respiratory infections trigger acute decompensation in heart failure; flu can tip a compensated patient into severe breathlessness
• Pneumococcal vaccine (PPSV23 and/or PCV15/20) - pneumonia is a major cause of hospitalization in cardiac patients
• COVID-19 boosters as per current schedule

Summary in One Table

The overarching message: she is asymptomatic but not safe. The heart is slowly deteriorating silently. Non-medication care - especially daily weight monitoring, salt control, structured walking, and regular echo surveillance - are what give her the best chance of catching deterioration early and staying out of hospital.